

ASX Announcement

14 July 2025

The Manager
Market Announcements Platform
Australian Securities Exchange Limited

NOTICE UNDER SECTION 708A(5)(e) OF THE CORPORATIONS ACT 2001 (CTH)

This notice is given by ReNerve Limited (ASX:RNV) (ReNerve or the Company) under section 708A(5)(e) of the Corporations Act 2001 (Cth) (the Act).

ReNerve has issued 773,260 fully paid ordinary shares (New Shares) at an issue price of \$0.10741 per New Share pursuant to the Appendix 2A announced to ASX on 14 July 2025.

For the purpose of section 708A(6) of the Act, the Company hereby notifies that:

- a) the Company issued the New Shares without disclosure to investors under Part 6D.2 of the Act;
- b) this notice is given under section 708A(5)(e) of the Act;
- c) as at the date of this notice, the Company has complied with:
 - (i) the provisions of Chapter 2M of the Act as they apply to the Company; and
 - (ii) sections 674 of the Act;
- d) as at the date of this notice, there is no information that is 'excluded information' of the type referred to in section 708A(7) or section 708A(8) of the Act that is required to be disclosed pursuant to section 708A(6)(e) of the Act.

This announcement has been approved for release by the Company's Board of Directors.

- ENDS -

For further information and enquiries, please contact:

Dr Julian Chick
CEO & Managing Director
ReNerve Ltd
+61 (03) 9482 3940
info@renerve.com.au



+61 (03) 9482 3940



157 Heidelberg Rd,
Northcote, VIC 3070



www.renerve.com.au

About ReNerve Limited (ASX:RNV)

ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients worldwide.

Proven Clinical Success

ReNerve's first flagship product, the FDA-cleared **NervAlign® Nerve Cuff**, is already making a dramatic difference in surgical outcomes across the United States. Recent clinical studies have demonstrated remarkable results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant improvement that's changing lives.

Comprehensive Product Portfolio

ReNerve is advancing a complete suite of nerve repair solutions:

- **NervAlign® Nerve Cuff** – Our bioabsorbable protective wrap, naturally absorbed within six months of surgery.
- **NervAlign® Nerve Graft** – Eliminating the need for patients to undergo additional sural nerve harvesting.
- **NervAlign® Bionic Nerve** – Next-generation combination technology for the most challenging nerve repairs.

Market Leadership and Growth

With demonstrated market traction since the Company's 2022 product launch, ReNerve achieved 38% revenue growth in FY24, reaching \$177k in sales. Our high-margin, scalable products are positioning us as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US\$1.96 billion in 2024 and is projected to reach \$6.2 billion by 2031.¹

Vision and Values

We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve surgery.

¹ Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)